COMPANY

Cullinan Therapeutics Inc.

HQ: Cambridge, MA source · cullinantherapeutics.com ↗ · New England

Keywords: oncology immunology autoimmune diseases cancer autoimmune disease Sjögren Sjogren Disease Sjogren's Syndrome Immune Thrombocytopenia Warm Autoimmune Hemolytic Anemia AML (Acute Myeloid Leukemia) Non Small Cell Lung Cancer EGFR Exon 20 Mutation SLE SLE (Systemic Lupus) Relapsed/Refractory Acute Myeloid Leukemia (AML) Myelodysplastic Syndrome NSCLC Multiple Myeloma NHL NHL, Relapsed, Adult Nasopharyngeal Carcinoma Nasopharyngeal Cancer CLN-978 CLN-049 CLN-619 Velinotamig specified dose on specified days. CLN-617 CLN-081 VK-2019

Location: Cambridge, MA · source · Oct 15, 2026

Profile checked Oct 10, 2026

12Trials (company is sponsor)

Timeline

2026-12 Trial start 1: A Phase 1b/2a Study of Velinotamig in Adults With Relapsed/Refractory ITP and wAIHA source ↗
Oct 15, 2026 Trial start 1: A Phase 1b Study of CLN-049 in Combination With Azacitidine and Venetoclax in AML Patients source ↗
Oct 1, 2025 Trial start Phase 1: A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Sjogren's Disease source ↗
May 19, 2025 Trial start Phase 1: A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Rheumatoid Arthritis source ↗
Jan 21, 2025 Trial start Phase 1: A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Systemic Lupus Erythematosus source ↗
Sep 3, 2024 Trial start Phase 1: A Study of CLN-619 (Anti-MICA/MICB Antibody) in Patients With Relapsed and Refractory Multiple Myeloma source ↗
Dec 12, 2023 Trial start Phase 1: CLN-617 Alone and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors source ↗
May 31, 2023 Trial start Phase 1: A Study of CLN-978 in Patients With Relapsed or Refractory (R/R) B Cell Non-Hodgkin Lymphoma (B-NHL) source ↗
Nov 18, 2021 Trial start Phase 1: CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) source ↗
Oct 29, 2021 Trial start Phase 1: A Study of CLN-619 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors source ↗
Oct 31, 2019 Trial start 1: A Phase 1/2 Trial of CLN-081 in Patients With Non-Small Cell Lung Cancer source ↗
Apr 4, 2019 Trial start 1: Phase 1/2a Study of VK-2019 in Patients With Epstein-Barr Virus (EBV)-Positive Nasopharyngeal Carcinoma (NPC) source ↗

Upcoming milestones

2026-11 (ESTIMATED) · Phase 1 · A Study of CLN-978 in Patients With Relapsed or Refractory (R/R) B Cell Non-Hodgkin Lymphoma (B-NHL) · NCT05879744
2026-12 (ESTIMATED) · Phase 1 · A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Systemic Lupus Erythematosus · NCT06613360
2027-01 (ESTIMATED) · Phase 1 · CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) · NCT05143996
Sep 30, 2027 (ESTIMATED) · 1 · A Phase 1b Study of CLN-049 in Combination With Azacitidine and Venetoclax in AML Patients · NCT07722767
Dec 30, 2027 (ESTIMATED) · Phase 1 · A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Rheumatoid Arthritis · NCT06994143
Mar 15, 2028 (ESTIMATED) · Phase 1 · A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Sjogren's Disease · NCT07041099
2029-01 (ESTIMATED) · 1 · A Phase 1b/2a Study of Velinotamig in Adults With Relapsed/Refractory ITP and wAIHA · NCT07738822

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) 12

Record	Title	Phase	Status	Start	Primary completion
NCT07041099	A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Sjogren's Disease	Phase 1	Recruiting	Oct 1, 2025	Mar 15, 2028 (estimated)
NCT07738822	A Phase 1b/2a Study of Velinotamig in Adults With Relapsed/Refractory ITP and wAIHA	1	Not yet recruiting	2026-12	2029-01 (estimated)
NCT07722767	A Phase 1b Study of CLN-049 in Combination With Azacitidine and Venetoclax in AML Patients	1	Not yet recruiting	Oct 15, 2026	Sep 30, 2027 (estimated)
NCT06035744	CLN-617 Alone and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors	Phase 1	Terminated	Dec 12, 2023	Jun 16, 2026 (actual)
NCT04036682	A Phase 1/2 Trial of CLN-081 in Patients With Non-Small Cell Lung Cancer	1	Active, not recruiting	Oct 31, 2019	Oct 13, 2025 (actual)
NCT06613360	A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Systemic Lupus Erythematosus	Phase 1	Recruiting	Jan 21, 2025	2026-12 (estimated)
NCT06994143	A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Rheumatoid Arthritis	Phase 1	Recruiting	May 19, 2025	Dec 30, 2027 (estimated)
NCT05143996	CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)	Phase 1	Recruiting	Nov 18, 2021	2027-01 (estimated)
NCT05117476	A Study of CLN-619 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors	Phase 1	Active, not recruiting	Oct 29, 2021	2026-03 (estimated)
NCT06381141	A Study of CLN-619 (Anti-MICA/MICB Antibody) in Patients With Relapsed and Refractory Multiple Myeloma	Phase 1	Active, not recruiting	Sep 3, 2024	2026-09 (estimated)
NCT05879744	A Study of CLN-978 in Patients With Relapsed or Refractory (R/R) B Cell Non-Hodgkin Lymphoma (B-NHL)	Phase 1	Active, not recruiting	May 31, 2023	2026-11 (estimated)
NCT03682055	Phase 1/2a Study of VK-2019 in Patients With Epstein-Barr Virus (EBV)-Positive Nasopharyngeal Carcinoma (NPC)	1	Terminated	Apr 4, 2019	Jun 23, 2020 (actual)